出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年7月
CT/NG検査市場 : 製品 (アッセイ、キット、分析装置)、検査タイプ (検査室、ポイントオブケア検査)、技術 (INAAT、PCR、免疫診断)、エンドユーザー (診断研究所、病院、診療所)、地域別 – 2028年までの世界予測
CT/NG Testing Market by Product (Assays, Kits & Analyzers), Test Type (Laboratory, Point-of-care Testing), Technology (INAAT, PCR, Immunodiagnostics), End User (Diagnostic Labs, Hospitals & Clinics) & Region – Global Forecast to 2028
| ページ数 | 182 |
| 図表数 | 162 |
| 種別 | 英文調査報告書 |
| 価格 |
The global CT/NG testing market is projected to reach USD 2.7 billion by 2028 from USD 1.7 billion in 2023, at a CAGR of 8.6% during the forecast period. Increasing prevalence of CT/NG infections, steady investments and funds in CT/NG and rising attempts in awareness for CT/NG diagnosis are factors driving the growth of this market. However high prices of CT/NG testing instruments and kits along with scarcity in technicians is likely to hamper the growth of CT/NG testing market.
“The assays and kits segment accounted for the highest market share during the forecast period”
Based on product, the global CT/NG testing market is segmented into two segments namely, assays & kits and instruments/analyzers. In 2022, the assays & kits segment accounted for the largest share of the CT/NG testing market. The rising growth of this segment is due to the continuous and high demand of assays & kits in comparison to instruments for diagnosis of the disease. The continuous purchase of assay & kits makes them a high recurring purchase which then directly influences the large size and high growth rate of this product segment.
“INAAT accounted for the highest growth during the forecast period”
Based on technology, the CT/NG testing market is broadly segmented into INAAT (isothermal nucleic acid amplification technology), PCR (polymerase chain reaction), immunodiagnostics and other technologies. In 2022, the INAAT (isothermal nucleic acid amplification technology) segment held the dominant position in the CT/NG testing market, representing the largest share. The large share of the INAAT segment can be attributed to several factors such as such as the rising prevalence of CT/NG, the cost benefits of INAAT, turnaround time of INAAT, the need for prompt diagnosis with high accuracy, and the increasing number of blood transfusions and donations.
“Asia Pacific: The fastest-growing region CT/NG testing market”
Based on the region segmentation, the CT/NG testing market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Emerging countries in this region have witnessed growth in their GDPs and a rise in disposable income levels. All this leading to increased healthcare spending, healthcare infrastructure modernization, and the rising penetration of clinical laboratory technologies in the Asia Pacific countries. These factors are expected to provide significant growth opportunities for CT/NG testing companies operating in this region.
Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
• By Designation: C-level (27%), Director-level (18%), and Others (55%)
• By Region: North America (51%), Europe (21%), Asia- Pacific (18%), Latin America (6%) and Middle East & Africa(4%)
Prominent companies include F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN (Netherlands), PerkinElmer Inc. (US), Bio-Rad Laboratories, Inc. (US), Siemens Healthineers AG (Germany), Danaher (US), Becton, Dickinson and Company (US), Seegene, Inc. (South Korea), Meridian Bioscience Inc. (US), Binx Health, Inc. (US), Visby Medical, Inc. (US), Geneproof A.S. (Czech Republic), Bioneer Corporation (South Korea), Genetic Signatures (Australia), Microbiologics, Inc. (US), Vircell S.L. (Spain), Sansure Biotech Inc. (China), ELITechGroup (France), Molbio Diagnostics Pvt. Ltd. (India), Operon S.A. (Spain), Tianlong Technology Co., Ltd. (China), and Goffin Molecular Technologies B.V. (Netherlands).
Research Coverage
This research report categorizes the CT/NG testing market by product, testing type, technology, end user, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CT/NG testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; Contracts, partnerships, agreements, new product & service launches, mergers and acquisitions, and recent developments associated with the CT/NG testing market. Competitive analysis of upcoming startups in the CT/NG testing market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall CT/NG testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the CT/NG testing market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the CT/NG testing market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the CT/NG testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the CT/NG testing market
• Competitive Assessment: In-depth assessment of market ranking, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), among others in the CT/NG testing market strategies.
目次
1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS AND EXCLUSIONS 25
1.3 STUDY SCOPE 25
1.3.1 MARKETS COVERED 25
1.3.2 GEOGRAPHIC SCOPE 26
1.3.3 YEARS CONSIDERED 26
1.4 CURRENCY CONSIDERED 27
1.5 LIMITATIONS 27
1.6 STAKEHOLDERS 27
1.7 SUMMARY OF CHANGES 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
2.2 RESEARCH APPROACH 29
FIGURE 1 CT/NG TESTING MARKET: RESEARCH DESIGN 29
2.2.1 SECONDARY DATA 30
2.2.1.1 Key data from secondary sources 30
2.2.2 PRIMARY DATA 31
2.2.2.1 Primary sources 32
2.2.2.2 Key data from primary sources 33
2.2.2.3 Key industry insights 34
2.2.2.4 Breakdown of primary interviews 34
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND
DEMAND-SIDE PARTICIPANTS 34
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 35
2.3 MARKET SIZE ESTIMATION 35
2.3.1 BOTTOM-UP APPROACH 36
2.3.1.1 Approach 1: Company revenue estimation approach 36
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 36
2.3.1.2 Approach 2: Presentations of companies and primary interviews 36
2.3.1.3 Growth forecast 37
2.3.1.4 CAGR projections 37
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37
2.3.2 TOP-DOWN APPROACH 37
FIGURE 6 CT/NG TESTING MARKET: TOP-DOWN APPROACH 38
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 39
FIGURE 7 DATA TRIANGULATION METHODOLOGY 39
2.5 MARKET SHARE ANALYSIS 40
2.6 STUDY ASSUMPTIONS 40
2.7 GROWTH RATE ASSUMPTIONS 40
2.8 RISK ASSESSMENT 41
2.8.1 CT/NG TESTING MARKET: RISK ASSESSMENT 41
2.9 RECESSION IMPACT 41
3 EXECUTIVE SUMMARY 44
FIGURE 8 CT/NG TESTING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 44
FIGURE 9 CT/NG TESTING MARKET, BY TESTING TYPE, 2023 VS. 2028 (USD MILLION) 45
FIGURE 10 CT/NG TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 45
FIGURE 11 CT/NG TESTING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 46
FIGURE 12 CT/NG TESTING MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 46
4 PREMIUM INSIGHTS 48
4.1 CT/NG TESTING MARKET OVERVIEW 48
FIGURE 13 INCREASING PREVALENCE OF CT/NG INFECTIONS TO DRIVE MARKET 48
4.2 CT/NG TESTING MARKET, BY PRODUCT, 2023 VS. 2028 48
FIGURE 14 ASSAYS AND KITS SEGMENT TO DOMINATE CT/NG TESTING MARKET IN 2028 48
4.3 CT/NG TESTING MARKET, BY TESTING TYPE, 2023 VS. 2028 49
FIGURE 15 LABORATORY TESTING SEGMENT TO DOMINATE MARKET IN 2028 49
4.4 CT/NG TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 49
FIGURE 16 PCR SEGMENT TO DOMINATE CT/NG TESTING MARKET
DURING STUDY PERIOD 49
4.5 CT/NG TESTING MARKET, BY END USER, 2023 VS. 2028 50
FIGURE 17 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET IN 2028 50
4.6 CT/NG TESTING MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 50
FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN CT/NG TESTING MARKET DURING FORECAST PERIOD 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 19 CT/NG TESTING MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 51
5.2.1 DRIVERS 52
5.2.1.1 Increasing prevalence of CT/NG infections 52
5.2.1.2 Increasing investments and initiatives in CT/NG 52
5.2.1.3 Growing awareness of early disease diagnosis in emerging economies 53
5.2.2 RESTRAINTS 54
5.2.2.1 Unfavorable reimbursement scenario for diagnostic companies 54
5.2.2.2 High cost of instruments and lack of budget for small laboratories and physicians’ offices 54
5.2.3 OPPORTUNITIES 55
5.2.3.1 Growth opportunities in emerging economies 55
5.2.4 CHALLENGES 55
5.2.4.1 Changing regulatory landscape in European Union and US 55
5.2.4.2 Operational barriers and shortage of skilled laboratory technicians 56
5.3 PRICING ANALYSIS 56
TABLE 1 AVERAGE SELLING PRICE OF CT/NG TESTING PRODUCTS (2023) 56
5.4 PATENT ANALYSIS 57
FIGURE 20 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2013–DECEMBER 2022) 57
5.4.1 LIST OF KEY PATENTS 58
5.5 VALUE CHAIN ANALYSIS 59
FIGURE 21 VALUE CHAIN ANALYSIS OF CT/NG TESTING MARKET: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES 60
5.6 SUPPLY CHAIN ANALYSIS 60
FIGURE 22 CT/NG TESTING MARKET: SUPPLY CHAIN ANALYSIS 61
5.7 ECOSYSTEM MARKET MAP 61
FIGURE 23 CT/NG TESTING MARKET: ECOSYSTEM MARKET MAP 62
5.7.1 CT/NG TESTING MARKET: ROLE IN ECOSYSTEM 62
5.8 PORTER’S FIVE FORCES ANALYSIS 63
TABLE 2 CT/NG TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 63
5.8.1 THREAT OF NEW ENTRANTS 63
5.8.2 THREAT OF SUBSTITUTES 63
5.8.3 BARGAINING POWER OF BUYERS 63
5.8.4 BARGAINING POWER OF SUPPLIERS 64
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 64
5.9 REGULATORY ANALYSIS 64
TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 65
TABLE 5 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65
TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 65
5.9.1 NORTH AMERICA 66
5.9.1.1 US 66
5.9.1.2 Canada 66
5.9.2 EUROPE 66
TABLE 7 EUROPE: CLASSIFICATION OF DEVICES 66
5.9.3 ASIA PACIFIC 67
5.9.3.1 China 67
5.9.3.2 Japan 67
TABLE 8 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 67
5.9.3.3 India 68
5.9.4 LATIN AMERICA 68
5.9.4.1 Brazil 68
5.9.4.2 Mexico 68
5.9.5 MIDDLE EAST 68
5.9.6 AFRICA 69
5.10 TRADE ANALYSIS 69
5.10.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS 69
TABLE 9 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION) 69
TABLE 10 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS,
BY COUNTRY, 2018–2022 (USD MILLION) 69
5.11 PESTLE ANALYSIS 70
5.12 TECHNOLOGY ANALYSIS 71
5.13 KEY CONFERENCES AND EVENTS IN 2023–2024 71
TABLE 11 CT/NG TESTING MARKET: DETAILED LIST OF CONFERENCES AND
EVENTS IN 2023–2024 71
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 73
5.14.1 REVENUE SHIFT AND REVENUE POCKETS FOR CT/NG TESTING
PRODUCT MANUFACTURERS 73
5.14.2 REVENUE SHIFT IN CT/NG TESTING MARKET 73
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 73
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 73
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
FOR CT/NG TESTING PRODUCTS 73
TABLE 12 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
FOR CT/NG TESTING PRODUCTS 74
5.15.2 BUYING CRITERIA 74
FIGURE 25 KEY BUYING CRITERIA FOR CT/NG TESTING PRODUCTS 74
TABLE 13 KEY BUYING CRITERIA FOR CT/NG TESTING PRODUCTS 74
6 CT/NG TESTING MARKET, BY PRODUCT 75
6.1 INTRODUCTION 76
TABLE 14 CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 76
6.2 ASSAYS AND KITS 76
6.2.1 RECURRENT REQUIREMENT AND PURCHASE OF ASSAYS AND
KITS TO DRIVE GROWTH 76
TABLE 15 KEY ASSAYS AND KITS OFFERED BY MARKET PLAYERS 77
TABLE 16 CT/NG TESTING MARKET FOR ASSAYS AND KITS, BY REGION,
2021–2028 (USD MILLION) 77
6.3 INSTRUMENTS/ANALYZERS 77
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST GROWTH 77
TABLE 17 KEY INSTRUMENTS/ANALYZERS OFFERED BY MARKET PLAYERS 78
TABLE 18 CT/NG TESTING MARKET FOR INSTRUMENTS/ANALYZERS, BY REGION, 2021–2028 (USD MILLION) 78
7 CT/NG TESTING MARKET, BY TESTING TYPE 79
7.1 INTRODUCTION 80
TABLE 19 CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 80
7.2 LABORATORY TESTING 80
7.2.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASING FOCUS ON EARLY DISEASE DETECTION TO DRIVE GROWTH 80
TABLE 20 CT/NG TESTING MARKET FOR LABORATORY TESTING, BY REGION,
2021–2028 (USD MILLION) 81
7.3 POINT-OF-CARE TESTING 81
7.3.1 FASTER TURNAROUND TIME TO DRIVE GROWTH 81
TABLE 21 CT/NG TESTING MARKET FOR POINT-OF-CARE TESTING, BY REGION,
2021–2028 (USD MILLION) 82
8 CT/NG TESTING MARKET, BY TECHNOLOGY 83
8.1 INTRODUCTION 84
TABLE 22 CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 84
8.2 PCR 84
8.2.1 GROWING USE OF PCR IN PROTEOMICS AND GENOMICS TO DRIVE GROWTH 84
TABLE 23 CT/NG TESTING MARKET FOR PCR, BY REGION, 2021–2028 (USD MILLION) 85
8.3 INAAT 85
8.3.1 COST-BENEFITS OF INAAT TO DRIVE GROWTH 85
TABLE 24 CT/NG TESTING MARKET FOR INAAT, BY REGION, 2021–2028 (USD MILLION) 86
8.4 IMMUNODIAGNOSTICS 86
8.4.1 RISING PREVALENCE OF CT/NG AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE GROWTH 86
TABLE 25 CT/NG TESTING MARKET FOR IMMUNODIAGNOSTICS, BY REGION,
2021–2028 (USD MILLION) 87
8.5 OTHER TECHNOLOGIES 87
TABLE 26 CT/NG TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION,
2021–2028 (USD MILLION) 88
9 CT/NG TESTING MARKET, BY END USER 89
9.1 INTRODUCTION 90
TABLE 27 CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 90
9.2 DIAGNOSTIC LABORATORIES 90
9.2.1 AVAILABILITY OF WIDE RANGE OF TEST PANELS FOR DISEASE
TESTING TO SUPPORT GROWTH 90
TABLE 28 CT/NG TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021–2028 (USD MILLION) 91
9.3 HOSPITALS AND CLINICS 91
9.3.1 INCREASING NUMBER OF HOSPITALS TO DRIVE GROWTH 91
TABLE 29 CT/NG TESTING MARKET FOR HOSPITALS AND CLINICS, BY REGION,
2021–2028 (USD MILLION) 92
9.4 OTHER END USERS 92
TABLE 30 CT/NG TESTING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 93
10 CT/NG TESTING MARKET, BY REGION 94
10.1 INTRODUCTION 95
TABLE 31 CT/NG TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 95
10.2 NORTH AMERICA 95
FIGURE 26 NORTH AMERICA: CT/NG TESTING MARKET SNAPSHOT 96
TABLE 32 NORTH AMERICA: CT/NG TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 33 NORTH AMERICA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 97
TABLE 34 NORTH AMERICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 97
TABLE 35 NORTH AMERICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 98
TABLE 36 NORTH AMERICA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 98
10.2.1 RECESSION IMPACT: NORTH AMERICA 98
10.2.2 US 99
10.2.2.1 Growing prevalence of infectious diseases to drive market 99
TABLE 37 US: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 99
TABLE 38 US: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 99
TABLE 39 US: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 100
TABLE 40 US: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 100
10.2.3 CANADA 100
10.2.3.1 Rising government initiatives to propel market growth in coming years 100
TABLE 41 CANADA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 101
TABLE 42 CANADA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 101
TABLE 43 CANADA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 101
TABLE 44 CANADA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 102
10.3 EUROPE 102
TABLE 45 EUROPE: CT/NG TESTING MARKET, BY COUNTRY,
2021–2028 (USD MILLION) 103
TABLE 46 EUROPE: CT/NG TESTING MARKET, BY PRODUCT,
2021–2028 (USD MILLION) 103
TABLE 47 EUROPE: CT/NG TESTING MARKET, BY TESTING TYPE,
2021–2028 (USD MILLION) 103
TABLE 48 EUROPE: CT/NG TESTING MARKET, BY TECHNOLOGY,
2021–2028 (USD MILLION) 104
TABLE 49 EUROPE: CT/NG TESTING MARKET, BY END USER,
2021–2028 (USD MILLION) 104
10.3.1 RECESSION IMPACT: EUROPE 104
10.3.2 GERMANY 105
10.3.2.1 Increasing healthcare expenditure to drive market growth 105
TABLE 50 GERMANY: CT/NG TESTING MARKET, BY PRODUCT,
2021–2028 (USD MILLION) 105
TABLE 51 GERMANY: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 105
TABLE 52 GERMANY: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 106
TABLE 53 GERMANY: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 106
10.3.3 UK 106
10.3.3.1 Growing number of accredited diagnostic laboratories to propel market growth 106
TABLE 54 UK: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 107
TABLE 55 UK: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 107
TABLE 56 UK: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 107
TABLE 57 UK: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 108
10.3.4 FRANCE 108
10.3.4.1 Rising R&D expenditure in France to drive market growth 108
TABLE 58 FRANCE: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 108
TABLE 59 FRANCE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 109
TABLE 60 FRANCE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 109
TABLE 61 FRANCE: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 109
10.3.5 ITALY 110
10.3.5.1 Adoption of advanced diagnostic technologies to favor growth 110
TABLE 62 ITALY: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 110
TABLE 63 ITALY: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 110
TABLE 64 ITALY: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 111
TABLE 65 ITALY: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 111
10.3.6 SPAIN 111
10.3.6.1 Growing demand for diagnostic testing in Spain to favor market growth 111
TABLE 66 SPAIN: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 112
TABLE 67 SPAIN: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 112
TABLE 68 SPAIN: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 112
TABLE 69 SPAIN: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 113
10.3.7 REST OF EUROPE 113
TABLE 70 REST OF EUROPE: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 113
TABLE 71 REST OF EUROPE: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 114
TABLE 72 REST OF EUROPE: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 114
TABLE 73 REST OF EUROPE: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 114
10.4 ASIA PACIFIC 115
FIGURE 27 ASIA PACIFIC: CT/NG TESTING MARKET SNAPSHOT 116
TABLE 74 ASIA PACIFIC: CT/NG TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 117
TABLE 75 ASIA PACIFIC: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 117
TABLE 76 ASIA PACIFIC: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 117
TABLE 77 ASIA PACIFIC: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 118
TABLE 78 ASIA PACIFIC: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 118
10.4.1 RECESSION IMPACT: ASIA PACIFIC 118
10.4.2 CHINA 119
10.4.2.1 Growing public access to modern healthcare to drive market growth 119
TABLE 79 CHINA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 119
TABLE 80 CHINA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 120
TABLE 81 CHINA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 120
TABLE 82 CHINA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 120
10.4.3 JAPAN 121
10.4.3.1 Universal healthcare reimbursement policy to drive market growth in Japan 121
TABLE 83 JAPAN: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 121
TABLE 84 JAPAN: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 122
TABLE 85 JAPAN: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 122
TABLE 86 JAPAN: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 122
10.4.4 INDIA 123
10.4.4.1 Increasing private and public investments in country’s healthcare system to drive market growth 123
TABLE 87 INDIA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 123
TABLE 88 INDIA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 124
TABLE 89 INDIA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 124
TABLE 90 INDIA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 124
10.4.5 REST OF ASIA PACIFIC 125
TABLE 91 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 125
TABLE 92 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 125
TABLE 93 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 126
TABLE 94 REST OF ASIA PACIFIC: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 126
10.5 LATIN AMERICA 126
10.5.1 IMPROVING HEALTHCARE INFRASTRUCTURE TO DRIVE GROWTH OF CT/NG TESTING MARKET IN LATIN AMERICA 126
TABLE 95 LATIN AMERICA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 127
TABLE 96 LATIN AMERICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 127
TABLE 97 LATIN AMERICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128
TABLE 98 LATIN AMERICA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 128
10.5.2 RECESSION IMPACT: LATIN AMERICA 128
10.6 MIDDLE EAST & AFRICA 129
10.6.1 LACK OF SKILLED RESOURCES TO RESTRICT MARKET GROWTH 129
TABLE 99 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 129
TABLE 100 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY TESTING TYPE, 2021–2028 (USD MILLION) 130
TABLE 101 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 130
TABLE 102 MIDDLE EAST & AFRICA: CT/NG TESTING MARKET, BY END USER, 2021–2028 (USD MILLION) 130
10.6.2 RECESSION IMPACT: MIDDLE EAST & AFRICA 131
11 COMPETITIVE LANDSCAPE 132
11.1 OVERVIEW 132
11.2 STRATEGIES OF KEY PLAYERS 132
11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN CT/NG TESTING MARKET 132
TABLE 103 OVERVIEW OF STRATEGIES DEPLOYED BY KEY CT/NG TESTING PRODUCTS MANUFACTURING COMPANIES 132
11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 134
FIGURE 28 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN CT/NG TESTING MARKET 134
11.4 MARKET SHARE ANALYSIS 134
11.4.1 CT/NG TESTING MARKET 134
FIGURE 29 CT/NG TESTING MARKET SHARE, BY KEY PLAYER (2022) 135
TABLE 104 CT/NG TESTING MARKET: DEGREE OF COMPETITION 135
11.5 COMPANY EVALUATION MATRIX, 2022 136
11.5.1 STARS 136
11.5.2 EMERGING LEADERS 136
11.5.3 PERVASIVE PLAYERS 137
11.5.4 PARTICIPANTS 137
FIGURE 30 CT/NG TESTING MARKET: COMPANY EVALUATION MATRIX, 2022 137
11.6 COMPANY EVALUATION MATRIX FOR START-UPS/SMES (2022) 138
11.6.1 PROGRESSIVE COMPANIES 138
11.6.2 STARTING BLOCKS 138
11.6.3 RESPONSIVE COMPANIES 138
11.6.4 DYNAMIC COMPANIES 138
FIGURE 31 CT/NG TESTING MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 139
11.7 COMPETITIVE BENCHMARKING 140
11.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS 140
FIGURE 32 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS 140
TABLE 105 CT/NG TESTING MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS 140
TABLE 106 PRODUCT FOOTPRINT OF COMPANIES 141
TABLE 107 REGIONAL FOOTPRINT OF COMPANIES 141
TABLE 108 CT/NG TESTING MARKET: DETAILED LIST OF KEY START-UPS/SMES 141
11.8 COMPETITIVE SCENARIO 142
11.8.1 PRODUCT LAUNCHES 142
TABLE 109 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS 142
11.8.2 DEALS 142
TABLE 110 KEY DEALS 142
12 COMPANY PROFILES 143
12.1 KEY PLAYERS 143
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 F. HOFFMANN-LA ROCHE LTD 143
TABLE 111 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 143
FIGURE 33 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 144
12.1.2 HOLOGIC, INC. 147
TABLE 112 HOLOGIC, INC.: BUSINESS OVERVIEW 147
FIGURE 34 HOLOGIC, INC.: COMPANY SNAPSHOT (2022) 148
12.1.3 THERMO FISHER SCIENTIFIC, INC. 150
TABLE 113 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 150
FIGURE 35 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 151
12.1.4 ABBOTT LABORATORIES 153
TABLE 114 ABBOTT LABORATORIES: BUSINESS OVERVIEW 153
FIGURE 36 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022) 154
12.1.5 PERKINELMER, INC. 156
TABLE 115 PERKINELMER, INC.: BUSINESS OVERVIEW 156
FIGURE 37 PERKINELMER, INC.: COMPANY SNAPSHOT (2022) 157
12.1.6 QIAGEN 159
TABLE 116 QIAGEN: BUSINESS OVERVIEW 159
FIGURE 38 QIAGEN: COMPANY SNAPSHOT (2022) 160
12.1.7 SIEMENS HEALTHINEERS AG 162
TABLE 117 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 162
FIGURE 39 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2022) 163
12.1.8 DANAHER 164
TABLE 118 DANAHER: BUSINESS OVERVIEW 164
FIGURE 40 DANAHER: COMPANY SNAPSHOT (2022) 165
12.1.9 BECTON, DICKINSON AND COMPANY 167
TABLE 119 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 167
FIGURE 41 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022) 168
12.1.10 BIO-RAD LABORATORIES, INC. 169
TABLE 120 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 169
FIGURE 42 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2022) 170
12.2 OTHER PLAYERS 172
12.2.1 SEEGENE, INC. 172
12.2.2 MERIDIAN BIOSCIENCE 173
12.2.3 GENETIC SIGNATURES 174
12.2.4 ELITECHGROUP 174
12.2.5 MOLBIO DIAGNOSTICS PVT. LTD. 175
12.2.6 BINX HEALTH, INC. 175
12.2.7 VISBY MEDICAL, INC. 176
12.2.8 GENEPROOF A.S. 176
12.2.9 BIONEER CORPORATION 177
12.2.10 MICROBIOLOGICS 178
12.2.11 SANSURE BIOTECH, INC. 178
12.2.12 VIRCELL 179
12.2.13 OPERON 179
12.2.14 TIANLONG 180
12.2.15 GOFFIN MOLECULAR TECHNOLOGIES 180
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 181
13.1 DISCUSSION GUIDE 181
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 184
13.3 CUSTOMIZATION OPTIONS 186
13.4 RELATED REPORTS 186
13.5 AUTHOR DETAILS 187